Cure trials expand as AI control fights intensify

Global active cure-related trials now total 21,374, while the last 24 hours added 16 new Wire signals and 18 new Cure research updates—an uncommon alignment of pipeline breadth and discovery velocity. The Wire’s dominant theme is control during the AI phase transition: Australia is being urged not to “water down” AI rules after evidence that AI training already used Australian artists’ works, while China uses outbound AI exports to mask domestic demand weakness and scam operators “super-charge” fraud through cloned brands and fake sites. On the positive side, Anthropic’s commitment to allocate 5% of shares to a public-benefit fund points to governance structures being built alongside capability gains. Stay clinical about the interface: AI progress will only translate into human benefit if control, provenance, and incentives are enforced—otherwise society pays first in fraud and regulatory dilution. The window is still open.